Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2024-10-22 3:24 pm Purchase | 13G | Dyne Therapeutics Inc. DYN | BlackRock Inc. | 7,794,217 7.8% | 7,794,217 (New Position) | View |
| 2024-04-04 7:04 pm Purchase | 13G | Dyne Therapeutics Inc. DYN | RA CAPITAL MANAGEMENT L.P. | 5,213,661 6.4% | 5,213,661 (New Position) | View |
| 2024-02-14 4:57 pm Purchase | 13G | Dyne Therapeutics Inc. DYN | CITADEL ADVISORS LLC | 3,072,587 5% | 91,263 (+3.06%) | View |
| 2024-02-14 08:39 am Sale | 13G | Dyne Therapeutics Inc. DYN | Deep Track Capital LP | 2,000,000 3.26% | -2,500,000 (-55.56%) | View |
| 2024-02-12 4:06 pm Sale | 13G | Dyne Therapeutics Inc. DYN | MPM BIOVENTURES 2018 L.P. | 3,451,303 4.3% | -1,519,596 (-30.57%) | View |
| 2024-02-09 4:09 pm Purchase | 13G | Dyne Therapeutics Inc. DYN | Atlas Venture Fund XI L.P. | 7,342,083 9.1% | 15,966 (+0.22%) | View |
| 2024-01-29 3:26 pm Purchase | 13G | Dyne Therapeutics Inc. DYN | BlackRock Inc. BLK | 3,788,682 6.2% | 1,195,158 (+46.08%) | View |
| 2024-01-19 4:38 pm Purchase | 13G | Dyne Therapeutics Inc. DYN | Deep Track Capital LP | 4,500,000 5.55% | 2,500,000 (+125.00%) | View |
| 2024-01-19 09:08 am Sale | 13G | Dyne Therapeutics Inc. DYN | Deep Track Capital LP | 2,000,000 3.26% | -684,200 (-25.49%) | View |
| 2023-02-14 4:29 pm Unchanged | 13G | Dyne Therapeutics Inc. DYN | Atlas Venture Fund XI L.P. | 7,326,117 14.1% | 0 (Unchanged) | View |
| 2023-02-14 3:53 pm Sale | 13G | Dyne Therapeutics Inc. DYN | Logos Global Management LP | 2,150,000 4.1% | -804,392 (-27.23%) | View |
| 2023-02-14 08:32 am Sale | 13G | Dyne Therapeutics Inc. DYN | Deep Track Capital LP | 2,684,200 5.15% | -132,750 (-4.71%) | View |
| 2023-02-14 08:02 am Purchase | 13G | Dyne Therapeutics Inc. DYN | CITADEL ADVISORS LLC | 2,981,324 5.7% | 116,524 (+4.07%) | View |
| 2023-02-10 4:31 pm Sale | 13D | Dyne Therapeutics Inc. DYN | Vida Ventures II LLC | 2,220,034 4.3% | -740,012 (-25.00%) | View |
| 2023-02-09 4:04 pm Purchase | 13G | Dyne Therapeutics Inc. DYN | MPM BIOVENTURES 2018 L.P. | 4,970,899 9.5% | 19,596 (+0.40%) | View |
| 2023-02-09 11:01 am Sale | 13G | Dyne Therapeutics Inc. DYN | BlackRock Inc. BLK | 2,593,524 4.9% | -25,094 (-0.96%) | View |
| 2023-02-08 2:57 pm Purchase | 13G | Dyne Therapeutics Inc. DYN | BlackRock Inc. BLK | 2,618,618 5% | 2,618,618 (New Position) | View |
| 2022-11-14 4:43 pm Sale | 13G | Dyne Therapeutics Inc. DYN | RA CAPITAL MANAGEMENT L.P. | 0 0% | -2,805,045 (Position Closed) | View |
| 2022-02-14 4:11 pm Unchanged | 13G | Dyne Therapeutics Inc. DYN | RA CAPITAL MANAGEMENT L.P. | 2,805,045 5.4% | 0 (Unchanged) | View |
| 2022-02-14 4:10 pm Sale | 13G | Dyne Therapeutics Inc. DYN | Logos Global Management LP | 2,954,392 5.7% | -940,000 (-24.14%) | View |